![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-desktop-headergif-65408.gif)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-mobile-headergif-45399.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Burke will market the fixed-dose combination drug, Consensi to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis.
Lead Product(s): Amlodipine Besylate,Celecoxib
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Coeptis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2020